Implementation
of Counterfeit Protection Systems
in the Pharmaceutical Industry
Objectives
The aim of this conference is to present both the regulatory authorities' activities and the pharmaceutical industry's activities to develop and establish appropriate counterfeit protection systems. The conference will focus on effective and affordable strategies, improve collaboration among regulators and pharmaceutical industry, and discuss actions in the global fight against counterfeit.
|
Speakers
- Andrea K Brunson,
Pfizer, USA
- Andy Charvill,
MHRA, UK
- Dr Domenico Di Giorgio,
Agenzia Italiana del Farmaco, Italy
- Prof. Dr. Ulrike Holzgrabe,
University of Würzburg,Germany
- David S. Howard,
Johnson & Johnson, USA
- Karl Metzger,
Welding GmbH & Co. KG, Germany
- Dr Chris Oldenhof,
DSM Anti-Infectives,The Netherlands
- Robert Rosito,
Essex Animal Health, Germany
- Michael S. Russo,
Eli Lilly & Company, USA
- Dr. Stephan Schwarze,
BayerHealthCare, Germany
- Harald Vogt,
SAP AG, Germany
- Dr. Martin Wesch,
Wesch & Buchenroth, Germany
|
Highlights
- Tryptophan, Gentamicin, Heparin –
What Will Happen Next?
- Worrying Trends in Europe and USA
- Anti-Counterfeit Activities by Regulatory Agencies
– WHO IMPACT Taskforce
– Different Approaches and Projects in
Europe
– The MHRA Anti-Counterfeit Strategy
– FDA Activities
- Industry Initiatives: EFPIA’S Proposal for Coding and
Identification – 2 D Data Matrix Code
- RFID
- Security Features for Packaging Materials
- The Invisible Danger of Rogue APIs
- Holistic Approach for Counterfeit Protection Management
- Challenges for Supply Chain
– Trader / Distributor
– Pharmaceutical Industry
- The Heparin Case – Legal Implications for QA and QPs
|
